DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT01508949

CompletedPhase 2

Effect of Liraglutide on Weight and Appetite in Obese Subjects With Type 2 Diabetes

NNC 90-1170 Mechanism of Action: A Single-centre, Randomised, Double-blind, Parallel-group, Placebo-controlled Trial Evaluating the Effect of NNC 90-1170 on Weight and Appetite in Obese Subjects With Type 2 Diabetes

Lead sponsor

Novo Nordisk A/S

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

1

Recruiting sites

—

Enrollment

35

actual

Study population

Obesity / overweight, Type 2 diabetes

Key I/E criteria

•BMI ≥27•HbA1c 6.5-12%

Primary endpoint

•Body weight, absolute change (kg)

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT01508949
Org study IDNN2211-1333

Timeline

Milestones

Study first posted2012-01-12estimated
Last update posted2023-11-02actual
Study start2001-06 (month precision)
Primary completion2002-03actual (month precision)
Study completion2002-03actual (month precision)

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Obesity / overweightType 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Type 2 diabetes mellitus
•Diet treated and/or subjects in monotherapy with sulphonylurea or repaglinide
•HbA1c for diet treated subjects 6.5-12%, both inclusive
•HbA1c for sulphonylurea or repaglinide treated subjects maximum 10%
•Body mass index (BMI) at least 27 kg/m^2
•Euthyroid subjects
•Fasting blood glucose 7-14 mmol/l

Exclusion criteria

•Impaired liver function
•Impaired renal function
•Cardiac problems
•Uncontrolled treated/untreated hypertension
•Recurrent severe hypoglycaemia as judged by the Investigator
•Known or suspected allergy to trial product or related products
•Use of any drug (except for OHAs (oral hypoglycaemic agents), which in the Investigator's opinion could interfere with the glucose level or body weight. Stable doses, for 3 months or greater, of thyroid hormone replacement are allowed

Endpoints (9)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Weight & body composition
3
Other (unclassified)
3
Glycemic / diabetes
1
Patient-reported / QoL
1
Safety / tolerability / PK
1

Weight & body composition

3 endpoints
Primary/protocol endpoint

Change in weight

Body weight, absolute change (kg)

change from baseline, improvement

Secondary/protocol endpoint

Total fat mass (assessed by use of DEXA (dual energy X-ray absorptiometry) scan)

Total fat mass

descriptive

Secondary/protocol endpoint

Waist circumference

Waist circumference, change

change from baseline, improvement

Glycemic / diabetes

1 endpoint
Secondary/protocol endpoint

HbA1c (Glycosylated Haemoglobin)

descriptive, improvement

LOINC 4548-4

Patient-reported / QoL

1 endpoint
Secondary/protocol endpoint

Appetite assessed in connection with the fixed breakfast meal (assessed by the use of VAS (visual analogue scale))

descriptive

Safety / tolerability / PK

1 endpoint
Secondary/protocol endpoint

Adverse events

Treatment-emergent AEs (any)

descriptive, event

Other (unclassified)

3 endpoints
Secondary/protocol endpoint/low confidence

Spontaneous energy intake assessed in connection to the ad libitum lunch meal

descriptive

Secondary/protocol endpoint/low confidence

Gastric emptying rate

descriptive

Secondary/protocol endpoint/low confidence

Energy expenditure

descriptive

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.